Vassiliki Pasoglou1, Nicolas Michoux2, Julien Van Damme3, Sandy Van Nieuwenhove2, Marin Halut2, Perrine Triqueneaux2, Bertrand Tombal3, Frédéric E Lecouvet2. 1. Department of Radiology, Centre Du Cancer and Institut de Recherche Expérimentale Et Clinique (IREC, IMAG), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium. vassiliki.pasoglou@uclouvain.be. 2. Department of Radiology, Centre Du Cancer and Institut de Recherche Expérimentale Et Clinique (IREC, IMAG), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium. 3. Department of Urology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.
Abstract
PURPOSE: It is generally accepted that when metastases develop in a patient with biochemical recurrence of prostate cancer (PCa), they follow a centrifuge pattern of seeding from the pelvis and that most patients enter the disease as oligometastatic. In this study, we used whole-body magnetic resonance imaging (WB-MRI) to assess the anatomical distribution of oligo- and polymetastatic disease and the impact of the initial treatment on this distribution in patients. MATERIALS AND METHODS: WB-MRI examinations of patients with a rising prostate-specific antigen (PSA) after radical treatment by surgery or/and radiotherapy were analyzed for disease recurrence. The patients were separated into three groups, based on the primary treatment: patients treated by radical prostatectomy without radiotherapy and with/without lymph node dissection (RP), patients treated only by radiotherapy or hormono-radiotherapy (RT) and patients treated with radical prostatectomy and adjuvant or salvage radiotherapy (RP + RT). Patients with ≤ 5 bone or/and node metastases were considered oligometastatic. Regional distributions of bone and lymph nodes metastases were reported using anatomical diagrams. Univariate and multivariable logistic regressions were performed to identify prognostic factors of relapse. RESULTS: The primary treatment (RP, RT, RP + RT), Gleason score, PSA at relapse, time between first diagnosis and recurrence did not influence the metastatic status (oligo vs. polymetastatic). Oligometastatic patients showed different distribution of bone metastases compared to the polymetastatic ones and the distribution of the oligometastatic disease was not influenced by the primary treatment. CONCLUSIONS: In this WB-MRI-based study, there was no evidence that the primary treatment influenced the metastatic status of the patient or the distribution of the oligometastatic disease.
PURPOSE: It is generally accepted that when metastases develop in a patient with biochemical recurrence of prostate cancer (PCa), they follow a centrifuge pattern of seeding from the pelvis and that most patients enter the disease as oligometastatic. In this study, we used whole-body magnetic resonance imaging (WB-MRI) to assess the anatomical distribution of oligo- and polymetastatic disease and the impact of the initial treatment on this distribution in patients. MATERIALS AND METHODS: WB-MRI examinations of patients with a rising prostate-specific antigen (PSA) after radical treatment by surgery or/and radiotherapy were analyzed for disease recurrence. The patients were separated into three groups, based on the primary treatment: patients treated by radical prostatectomy without radiotherapy and with/without lymph node dissection (RP), patients treated only by radiotherapy or hormono-radiotherapy (RT) and patients treated with radical prostatectomy and adjuvant or salvage radiotherapy (RP + RT). Patients with ≤ 5 bone or/and node metastases were considered oligometastatic. Regional distributions of bone and lymph nodes metastases were reported using anatomical diagrams. Univariate and multivariable logistic regressions were performed to identify prognostic factors of relapse. RESULTS: The primary treatment (RP, RT, RP + RT), Gleason score, PSA at relapse, time between first diagnosis and recurrence did not influence the metastatic status (oligo vs. polymetastatic). Oligometastatic patients showed different distribution of bone metastases compared to the polymetastatic ones and the distribution of the oligometastatic disease was not influenced by the primary treatment. CONCLUSIONS: In this WB-MRI-based study, there was no evidence that the primary treatment influenced the metastatic status of the patient or the distribution of the oligometastatic disease.
Authors: Eva Dyrberg; Helle W Hendel; Tri Hien Viet Huynh; Tobias Wirenfeldt Klausen; Vibeke B Løgager; Claus Madsen; Erik M Pedersen; Maria Pedersen; Henrik S Thomsen Journal: Eur Radiol Date: 2018-08-21 Impact factor: 5.315
Authors: Sonya Youngju Park; Claudia Zacharias; Caitlyn Harrison; Richard E Fan; Christian Kunder; Negin Hatami; Frederik Giesel; Pejman Ghanouni; Bruce Daniel; Andreas M Loening; Geoffrey A Sonn; Andrei Iagaru Journal: Radiology Date: 2018-05-22 Impact factor: 11.105
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Anwar R Padhani; Frederic E Lecouvet; Nina Tunariu; Dow-Mu Koh; Frederik De Keyzer; David J Collins; Evis Sala; Stefano Fanti; H Alberto Vargas; Giuseppe Petralia; Heinz Peter Schlemmer; Bertrand Tombal; Johann de Bono Journal: Eur Urol Focus Date: 2016-07-15
Authors: Anwar R Padhani; Frederic E Lecouvet; Nina Tunariu; Dow-Mu Koh; Frederik De Keyzer; David J Collins; Evis Sala; Heinz Peter Schlemmer; Giuseppe Petralia; H Alberto Vargas; Stefano Fanti; H Bertrand Tombal; Johann de Bono Journal: Eur Urol Date: 2016-06-14 Impact factor: 20.096
Authors: Philip Sutera; Kim Van Der Eecken; Amar U Kishan; Anis Hamid; Emily Grist; Gerhardt Attard; Tamara Lotan; Adrianna A Mendes; Channing J Paller; Michael A Carducci; Ashley Ross; Hao Wang; Ken Pienta; Felix Y Feng; Emmanuel S Antonarakis; Piet Ost; Daniel Y Song; Stephen Greco; Curtiland Deville; Theodore DeWeese; Phuoc T Tran; Matthew P Deek Journal: Prostate Cancer Prostatic Dis Date: 2022-01-11 Impact factor: 5.455